Cargando…
The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia
PURPOSE: To assess ibrutinib pharmacokinetics under fasted and fed conditions, impact of food-intake timing, and the safety and tolerability. METHODS: Three studies were analyzed. Study 1 was a randomized, open-label, single-dose, four-way crossover study in 44 healthy participants. Study 2 was a ra...
Autores principales: | de Jong, Jan, Sukbuntherng, Juthamas, Skee, Donna, Murphy, Joe, O’Brien, Susan, Byrd, John C., James, Danelle, Hellemans, Peter, Loury, David J., Jiao, Juhui, Chauhan, Vijay, Mannaert, Erik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4419161/ https://www.ncbi.nlm.nih.gov/pubmed/25724156 http://dx.doi.org/10.1007/s00280-015-2708-9 |
Ejemplares similares
-
Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants
por: de Jong, Jan, et al.
Publicado: (2015) -
Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6
por: de Jong, Jan, et al.
Publicado: (2020) -
Outcomes with ibrutinib by line of therapy and post‐ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis
por: O'Brien, Susan M., et al.
Publicado: (2019) -
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
por: Woyach, Jennifer A., et al.
Publicado: (2023) -
Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single‐agent ibrutinib
por: Jones, Jeffrey A., et al.
Publicado: (2017)